Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Neurocrine (NBIX) today and set a price target of $127. The company’s shares opened today at $80.51.
Duncan observed:
“We are Overweight NBIX. We like NBIX’s top-tier performance with its Ingrezza launch in Tardive’s dyskinesia and believe recent FDA approval and Orilissa launch could generate substantial milestone / royalty revs from blockbuster opportunities. We also see potential upside from other indications/assets, including Opicapone in Parkinson’s (revs potentially in 2020) and NBI-74788 in congenital adrenal hyperplasia.”
According to TipRanks.com, Duncan is a 3-star analyst with an average return of 2.0% and a 46.8% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Crinetics Pharmaceuticals Inc, and KalVista Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $105.09 average price target.
See today’s analyst top recommended stocks >>
Neurocrine’s market cap is currently $7.27B and has a P/E ratio of 443.08. The company has a Price to Book ratio of 15.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.
